Your browser doesn't support javascript.
loading
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti, A; Felip, E; Matito, J; Mereu, E; Navarro, A; Cedrés, S; Pardo, N; Martinez de Castro, A; Remon, J; Miquel, J M; Guillaumet-Adkins, A; Nadal, E; Rodriguez-Esteban, G; Arqués, O; Fasani, R; Nuciforo, P; Heyn, H; Villanueva, A; Palmer, H G; Vivancos, A.
Afiliación
  • Martinez-Marti A; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona;; Autonomous University of Barcelona (UAB), Barcelona.
  • Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona;; Autonomous University of Barcelona (UAB), Barcelona;. Electronic address: efelip@vhio.net.
  • Matito J; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Mereu E; Single Cell Genomics Group, Centro Nacional de Análisis Genómico (CNAG) - Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona;; Pompeu Fabra University (UPF), Barcelona.
  • Navarro A; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Cedrés S; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Pardo N; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona;; Autonomous University of Barcelona (UAB), Barcelona.
  • Martinez de Castro A; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Remon J; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona;; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Miquel JM; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Guillaumet-Adkins A; Single Cell Genomics Group, Centro Nacional de Análisis Genómico (CNAG) - Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona;; Pompeu Fabra University (UPF), Barcelona.
  • Nadal E; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO) Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona;; Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet, Barcelona.
  • Rodriguez-Esteban G; Single Cell Genomics Group, Centro Nacional de Análisis Genómico (CNAG) - Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona;; Pompeu Fabra University (UPF), Barcelona.
  • Arqués O; Stem Cells and Cancer Group.
  • Fasani R; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
  • Heyn H; Single Cell Genomics Group, Centro Nacional de Análisis Genómico (CNAG) - Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona;; Pompeu Fabra University (UPF), Barcelona.
  • Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO) Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona;; Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spa
  • Palmer HG; Stem Cells and Cancer Group.
  • Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona;. Electronic address: avivancos@vhio.net.
Ann Oncol ; 28(10): 2451-2457, 2017 Oct 01.
Article en En | MEDLINE | ID: mdl-28961841
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Proteínas Proto-Oncogénicas c-met / Receptores ErbB / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Proteínas Proto-Oncogénicas c-met / Receptores ErbB / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Año: 2017 Tipo del documento: Article